Nutritional risk during GLP-1 therapy is primarily intake-driven rather than malabsorptive in origin
This hormone regulates blood sugar, slows stomach emptying, and signals fullness to your brain
Register today at #valueaddedmedicines #pharma #strategy #505b2 #innovation #healthcare #lifesciences To view or add a comment, sign in DCAT (Drug, Chemical & Associated Technologies Association) Week 2026: One Month to Go With one month remaining, preparations are accelerating across the pharmaceutical and life sciences industry for DCAT Week 2026, scheduled for March 2326 in New York City
my current routine looks like this: i take the burn capsules about 4x a week (not every day)
The prescribing doctor must document the members current baseline weight (within 30 days)
Stephen Appezzato Key Takeaways Federal exclusion of weight-loss drugs forces Medicare GLP-1 utilization into other FDA-approved indications, even as 2024 Part D gross GLP-1 spending reached $27.5 billion across 21.8 million claims
